The pregnane X receptor agonist st johns wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide

Clinical Pharmacokinetics

Volumn 50, Issue 9, 2011, Pages 605-611

  Fan, Lan ^a   Zhou, Gan ^a   Guo, Dong ^a   Liu, Ya Li ^a   Chen, Wang Qing ^a   Liu, Zhao Qian ^a   Tan, Zhi Rong ^a   Sheng, Deng ^a   Zhou, Hong Hao ^a   Zhang, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antihyperglycaemics; Drug interactions; Hypericum; Repaglinide; Repaglinide.

Indexed keywords

GLUCOSE; HYPERICUM PERFORATUM EXTRACT; ORGANIC ANION TRANSPORTER 1; PLACEBO; PREGNANE X RECEPTOR; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERICUM PERFORATUM; INSULIN BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

CARBAMATES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; GENOTYPE; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; HYPOGLYCEMIC AGENTS; ORGANIC ANION TRANSPORTERS; PHYTOTHERAPY; PIPERIDINES; PLACEBOS; PLANT EXTRACTS; RECEPTORS, STEROID; YOUNG ADULT;

EID: 80051494744     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11587310-000000000-00000     Document Type: Article

References (33)

1. Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. Postgrad Med 2002 Jul-Sep; 48 (3): 246-8 (Pubitemid 35386098)
2. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41 (7): 471-83 (Pubitemid 34804160)
3. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44 (12): 1209-25 (Pubitemid 41832564)
4. Kalliokoski A, Backman JT, Neuvonen PJ, et al. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 2008 Nov; 18 (11): 937-42
5. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005 Jun; 77 (6): 468-78 (Pubitemid 40824960)
6. Kajosaari LI, Laitila J, Neuvonen PJ, et al. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005 Oct; 97 (4): 249-56 (Pubitemid 41433700)
7. Niemi M, Backman JT, Neuvonen M, et al. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000 Nov; 68 (5): 495-500
8. Kalliokoski A, Backman JT, Kurkinen KJ, et al. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 2008 Oct; 84 (4): 488-96
9. Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005 Oct; 78 (4): 388-99 (Pubitemid 41393674)
10. Borrelli F, Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009 Dec; 11 (4): 710-27
11. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004 Jun; 18 (2): 262-76 (Pubitemid 38954916)
12. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002 Oct; 54 (4): 349-56 (Pubitemid 35334946)
13. Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000 Jun 20; 97 (13): 7500-2 (Pubitemid 30431492)
14. Watkins RE, Maglich JM, Moore LB, et al. 2.1 A crystal structure of human PXR in complex with the St John's wort compound hyperforin. Biochemistry 2003 Feb 18; 42 (6): 1430-8 (Pubitemid 36205949)
15. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-andAfrican-Americans. J Biol Chem 2001 Sep 21; 276 (38): 35669-75
16. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001 Oct; 11 (7): 597-607 (Pubitemid 32953585)
17. Zhang W, He YJ, Han CT, et al. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br J Clin Pharmacol 2006 Nov; 62 (5): 567-72 (Pubitemid 44571578)
18. Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-2 (Pubitemid 30431492)
19. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23 (Pubitemid 28419246)
20. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998; 95: 12208-13 (Pubitemid 28483744)
21. Bidstrup TB, Stilling N, Damkier P, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004 Apr; 60 (2): 109-14 (Pubitemid 38626440)
22. Hatorp V, Hansen KT, Thomsen MK. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003; 43: 649-60 (Pubitemid 36613124)
23. Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001Dec; 299 (3): 849-57 (Pubitemid 33104951)
24. Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol 2010 Feb; 50 (2): 205-13
25. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003 Apr; 31 (4): 421-31 (Pubitemid 36378519)
26. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol 2008 Mar; 48 (3): 311-21 (Pubitemid 351257770)
27. Kalliokoski A, Neuvonen M, Neuvonen PJ, et al. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008 Dec; 66 (6): 818-25
28. Meyer zu SchwabedissenHE,Kim RB.HepaticOATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm 2009 Nov-Dec; 6 (6): 1644-61
29. Kamiyama Y, Matsubara T, Yoshinari K, et al. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet 2007 Aug; 22 (4): 287-98
30. Meyer zu Schwabedissen HE, Bö ttcher K, Chaudhry A, et al. Liver X receptor a and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology 2010 Nov; 52 (5): 1797-807
31. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-40 (Pubitemid 39313123)
32. Mueller SC, Majcher-Peszynska J, Mundkowski RG, et al. No clinically relevant CYP3A induction after St John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-7
33. Will-Shahab L, Bauer S, Kunter U, et al. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009; 65: 287-94